Specialized Working Group on Adult Acute Lymphoblastic Leukemia

Overview

The Adult Acute Lymphoblastic Leukemia (Adult ALL) SWG is dedicated to furthering our understanding and spreading knowledge of the treatment of this condition.  

We’re a community of members that consists mostly of the European Working Group for Adult ALL (EWALL) group. The Adult ALL SWG includes the leaders of each European national ALL study groups. 

Our areas of focus are: 

  • Diagnostics—the identification of new genetic markers, particularly to define the new ALL subgroups ETP (Early T-Precursor ALL), bcr-abl-like-ALL 
  • Minimal residual disease—the EWALL study group is leading in the standardization of the different methods for MRD, particularly immunophenotyping, RT-PCR, and ongoing, NGS 
  • The treatment and patient care of adolescents and young adults (AYA) 
  • The treatment and patient care in older ALL patients 
  • The development of joint treatment approaches including prospective clinical trials 
  • The exploration of targeted therapies—EWALL is preparing in sequential studies of 1st, 2nd, and 3rd generation tyrosine kinase inhibitors 
  • The development of targeted therapies by immunotherapy 
  • The development of joint meta-analyses 
  • Ensuring the cooperation of the pharmaceutical industry for the optimal evaluation of new compounds in ALL, either in company sponsored or investigator-initiated trials
  • Develop guidelines and consensus recommendations for the management of ALL 

Join us

If you work in our field and share our mission to advance our understanding and treatment of Adult ALL, you’d be welcome to join our SWG. However, before you apply, we recommend you read our application guidance. 

Ready? Apply to join us on the EHA Portal.  

If you have any questions, please email our SWGs team.

 

SWG Educational Activities Publications Chairs and Members Highlights from the SWG
Share